SLNBs Feasible After Wide Local Excisions in Melanoma of the Head and Neck
Sentinel nodes were accurately identified in all 30 patients who underwent WLE.
All articles by James Nam
No Survival Benefit in Melanoma With Adjuvant Vemurafenib
Vemurafenib adjuvant therapy does not improve disease-free survival among patients with resected stage IIC to IIIB melanoma.
Subset of Metastatic Melanoma Patients May Be Cured With Pembrolizumab
Pembrolizumab leads to a durable complete response with low rates of relapse — even 2 years after discontinuation — and may cure a subset of patients with metastatic melanoma.
Melatonin Derivatives May Have Antitumor Properties in Melanoma
Researchers examined the changes in levels of different proteins in cancer cell lines after treatment with melatonin analogues
Melanoma Combination Treatment Gets Breakthrough Therapy Designation
Dabrafenib plus trametinib is the first adjuvant therapy indicated specifically for melanoma with the BRAFV600 mutation.
Melanoma Benefits From Trametinib Plus Adjuvant Dabrafenib
Patients who received adjuvant therapy with dabrafenib and trametinib had an estimated 3-year rate of relapse-free survival.
Genetic Melanoma Risk Prompts More Conversations Between Patients, Providers
Patients who are aware of their personal genetic risk for melanoma may have more conversations about skin cancer with their doctors.
Nivolumab Does Not Prolong Survival in Advanced Melanoma Post-Ipiliumab Tx
More than 50% of patients with melanoma do not benefit from therapy with ipilimumab and BRAF-inhibitors.
Pembrolizumab, Reduced-Dose Ipilimumab Safe for Advanced Melanoma
The standard dose pembrolizumab along with 4 doses of reduced dose ipilimumab may have good outcomes for patients with advanced melanoma.
Ipilimumab Gets Expanded Indication for Pediatric Melanoma
Pediatric patients with unresectable or metastatic melanomaare now included in the indication of IV ipilimumab.
-
Loading...
-
Loading...
Next post in Skin Cancer
